Prolato Clinical Research Center | Houston, TX
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
300 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Reference Study ID Number: CA42750 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal